IL35521A - Method for separating fermentation products - Google Patents
Method for separating fermentation productsInfo
- Publication number
- IL35521A IL35521A IL35521A IL3552170A IL35521A IL 35521 A IL35521 A IL 35521A IL 35521 A IL35521 A IL 35521A IL 3552170 A IL3552170 A IL 3552170A IL 35521 A IL35521 A IL 35521A
- Authority
- IL
- Israel
- Prior art keywords
- water
- broth
- solvent
- fermentation product
- fermentation
- Prior art date
Links
- 238000000855 fermentation Methods 0.000 title claims description 41
- 230000004151 fermentation Effects 0.000 title claims description 41
- 238000000034 method Methods 0.000 title claims description 41
- 239000000047 product Substances 0.000 claims description 67
- 239000002904 solvent Substances 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 239000003960 organic solvent Substances 0.000 claims description 25
- 238000004821 distillation Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Natural products S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 claims description 14
- 229960005358 monensin Drugs 0.000 claims description 14
- 229930191564 Monensin Natural products 0.000 claims description 13
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 13
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical group C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 13
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 12
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 10
- 229930195708 Penicillin V Natural products 0.000 claims description 9
- 229940056367 penicillin v Drugs 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- 229960003276 erythromycin Drugs 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229940056360 penicillin g Drugs 0.000 claims description 2
- BTEYIHUKHHAVAN-KDKWOIFOSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BTEYIHUKHHAVAN-KDKWOIFOSA-N 0.000 claims 1
- 241000384110 Tylos Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 28
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- HOKIDJSKDBPKTQ-GLXFQSAKSA-M cephalosporin C(1-) Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H]([NH3+])C([O-])=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-M 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 229930182555 Penicillin Natural products 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 229940049954 penicillin Drugs 0.000 description 8
- 235000019445 benzyl alcohol Nutrition 0.000 description 7
- 239000007791 liquid phase Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- YJJWILCYIMMPAS-VALXSNPUSA-N (2z)-2-[(3r,4s,5s,6r,7r,8s,9s,10r,13r,14s,16s)-6,16-diacetyloxy-3,7-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid Chemical compound C1C[C@H]2\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]2(C)[C@@]2(C)[C@@H](O)[C@H](OC(C)=O)[C@H]3[C@H](C)[C@H](O)CC[C@]3(C)[C@@H]21 YJJWILCYIMMPAS-VALXSNPUSA-N 0.000 description 5
- 229930194936 Tylosin Natural products 0.000 description 5
- 239000004182 Tylosin Substances 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- -1 lnvertase Proteins 0.000 description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
- 229910052753 mercury Inorganic materials 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 5
- 229960004059 tylosin Drugs 0.000 description 5
- 235000019375 tylosin Nutrition 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940072049 amyl acetate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical class [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 1
- KDGICAMBJAHGLO-UHFFFAOYSA-N (2-chloroacetyl) propanoate Chemical compound CCC(=O)OC(=O)CCl KDGICAMBJAHGLO-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241001619326 Cephalosporium Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000011552 falling film Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003117 prednisolones Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P37/00—Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
- C07C51/44—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation by distillation
- C07C51/46—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation by distillation by azeotropic distillation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
- C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
- C12P35/06—Cephalosporin C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/48—Tricarboxylic acids, e.g. citric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cephalosporin Compounds (AREA)
Description
METHOD FOR SEPARATING FERMENTATION PRODUCTS This Invention relates to a method for separating a fermentation product which does not boil below about 200°C. from the aqueous fermentation broth which comprises adding to the broth an organic solvent which forms an azeotrope with water and in which water Is soluble to an extent of less than about 10 gc of water per 100 g. of solvent at 25°C; subjecting the mixture to azeotroplc distillation to remove water until the water remaining in the mixture Is soluble in the organic solvent remaining and recovering the fermentation product from the distillation residue, the amount of organic solvent added to the fermentation broth being in excess of the amount needed to azeotropically remove substantially all the water.
The method of recovering the fermentation product from the distillation residue will vary depending upon whether or not the product is soluble in the organic solvent as will be discussed in more detail below.
This process is one of general applicability to nonvolatile fermentation products. There is no competi-tion between the organic solvent and water for the fermentation product as is the case when an extraction procedure is used. In addition, waste disposal problems are minimized since the water taken overhead during the azeotroplc distillation Is free of contamination and other byproducts are obtained in concentrated form for easy handling.
It is well known to prepare a number of products by fermentation processes utilizing microorganisms. The mixture present at the conclusion of the fermentation process is known as the fermentation whole broth. This broth is a dilute aqueous solution of the desired product containing a number of other materials such as mycelium, spores, unused nutrients, and various impurities. The desired product must be separated from this broth and purified for use. i A number of different methods have been used in the past to separate the product from the broth. One such method of separation of nitrogen basic antibiotics described in United States Patent 2,736,831 involves con-tacting the broth, with or without prior filtration, with a particulate cation exchange resin and eluting the antibiotic from the resin with a dilute acid solution. This process has limited utility since it can be applied only to basic materials. Further, the treated whole broth has had only the antibiotic removed and must be subjected to further extensive treatment to remove other components before it can be discharged as a waste stream.
A second method of separation that can be used with water soluble, organic solvent soluble antibiotics involves a multistage solvent extraction of the broth.
The broth may or may not be filtered prior to the extraction. This process also has limited utility. Further, it is impossible to completely remove all the product from the broth regardless of the number of extraction steps employed, and therefore, there is loss of product with the aqueous waste stream. Both the filter cake and the extracted broth present troublesome waste disposal problems .
For convenience in describing the process of the present Invention, fermentation products are divided - into four Glasses depending upon the solubility of the product in water and the organic solvent used in the process. These four classes are: 1„ Water soluble, solvent soluble 2. Water soluble, solvent insoluble 3. Water insoluble, solvent soluble 4. Water insoluble, solvent insoluble This process, in its various embodiments, can be used to separate fermentation products falling into any of the above categories, but from a practical standpoint will be used primarily when a product falling into one of the first three classes is involved.
The basic process is the same regardless of the class into which the fermentation product falls. Simply stated, the process comprises adding to the aqueous fermentation broth an organic solvent which forms an azeo-trope with water and in which water is soluble to an extent of less than 10 g. per 100 g. of solvent at 25°C, subjecting the mixture to azeotropic distillation to re-move water until the water remaining is soluble in the organic solvent and recovering the fermentation product from the distillation residue. The manner in which recovery of the product from the residue is accomplished is a function of the solubility characteristics of the product o If the product is in class 1 or 3 it will be in solution in the organic solvent at the completion of the azeotropic distillation. Insoluble by-products can then be separated by some suitable means such as filtration or centrifugation to obtain a solution of the desired product in the organic solvent. The product can then be recovered from the solution by any well-known procedure such as evaporation of the solvent , precipitation by the addition of a nonsolvent or extraction» For those solvent insoluble products falling into classes 2 and , recovery is accomplished by filtration or centrifugation of the residue from the azeotroplc distillation. Solvent insoluble products are contaminated with other insoluble solid by-products .further complicat-ing their purification. For this reason this process is more likely to be used to recover those products that are solvent soluble.
In the case of water soluble products, whether solvent soluble or solvent insoluble, the aqueous broth may be filtered prior to the addition of the organic solvent to remove water insoluble by-products. Such a filtration step might simplify later purification procedures. This is particularly true in the. case of water soluble, solvent insoluble products, Subject to the limitations discussed in the preceding paragraphs this process can be used in the recovery of any nonvolatile fermentation product which does not boil below about 200°C. A large number of such products are presently produced on a commer-cial scale. A list of such products may be found in Biochemical Engineering by Aiba, Humphrey and MiIlls, page 11, Academic Press (I965). Included in such a list are antibiotics such as bacitracin, chloramphenicol, cephalosporins, erythromycin, neomycin, penicillins, streptomycin, tylosin and vancomy-cin; steroids such as cortisone, hydrocortisone, predniso- lones and methylprednisolone; enzymes such as amylase, catalase, glucose oxidase, lnvertase, lipase, and penicillinase; organic acids such as citric, lactic, gluconic, and glutamic acids j vitamins and related products such as riboflavin, gibberellin, xanthophylls, torula yeast, and vitamin B^gJ polymers such as dextran; and various miscellaneous fermentation products.
This recovery process is also applicable to fermentation products that have been modified by chemical treatment in the fermentation broth prior to recovery, and as used herein the term "fermentation product" is intended to include such chemically modified materials.
Chemical modification might be done to aid · in the recovery of the product or to give a more desirable product „ Examples of chemical modification include the acidification of penicillin V whole broth to convert the penicillin V salt to penicillin V acid and the conversion of cephalosporin C to N-chloroacetylcephalospor.in C in the fermentation broth by treatment with chloroacetyl chloride or a mixed chloroacetyl anhydride.
The solvent to be used in the process is one that forms an azeotrope with water and which is a limited solvent for water. Thus, the solvent is preferably one in which water is soluble to the extent of no more than about 10 g„ per 100 g„ of solvent at 25°C. In general, aliphatic alcohols containing from about four to about eight carbon atoms are good solvents, as are the esters of the&e alcohols with lower aliphatic acids, particularly acetic acid. Other classes of suitable solvents include the halogenated lower alkanes, ketones containing at - - least five carbon atoms, and aromatic hydrocarbons.
Specific examples of suitable solvents include butyl alcohol, arayl alcohol, hexyl alcohol, benzyl alcohol, butyl acetate, amyl acetate, 1,2-dichloro'ethane, penta-none-3, hexanone-2, eyelohexanone, benzene, toluene, and the xylenes. This list is merely illustrative and is not intended to limit the class of solvents that may be used in any respect. Those skilled in the art are familiar with solvents forming azeotropes wi h, water . This inven-tion does not lie in which solvents will form such azeotropes but in the fact that these solvents may be used in our process for removing fermentation products from the broth. The particular solvent selected in any given case will depend upon the solubility characteristics of the product being removed.
The amount of solvent added will depend upon a number of factors, including the amount of water present in the broth, the composition of the water-solvent azeo-trope, and the solubility of water and the product in the solvent. Sufficient solvent should be added to azeotrop-ieally remove water until a single liquid phase remains. Thus, water should be azeotropically removed until the water remaining is soluble in the solvent present in the distillation vessel. Substantially all the water can be removed if desired. If the product being removed is soluble in the solvent, there should be sufficient solvent present after the azeotropic distillation to completely dissolve all the product. The solvent can be added all at once or can be added continuously or in increments over a period of time. Solvent taken overhead in the azeotrope can be recycled after separation from the water.
The azeotroplc distillation step can be carried out at atmospheric or reduced pressure, all In accordance with known chemical engineering techniques. If the desired product is heat-sensitive, it will be desirable to conduct the distillation at reduced pressure in order to achieve a lower temperature.
After the azeotrope has been condensed and allowed to cool it may be separated into the aqueous and solvent phases. The aqueous phase, after stripping to remove any dissolved solvent, can be discharged to the sewer. Because of the way in which the water is removed it is free of contaminants and does not need to be subjected to a waste disposal process. The solvent may be recycled to the process.
At the completion of the azeotroplc distillation the product may be recovered from the distillation residue in accordance with one of the procedures described above. Typical of those products which are sol-uble both in water and organic solvents are penicillin V, penicillin G, tylosin and erythromycin. These products are present in solution in the distillation residue.
An example of a product which is soluble in water but is insoluble in organic solvents is cephalosporin C, This product may be recovered from the residue by filtration, A typical example of a fermentation prod-uct that is insoluble in water but soluble in organic solvents is monensin. This ' product too, would be present in solution in the residue from the distillation, Once the product has been separated from the - - distillation residue, it can be purified in the manner heretofore employed for its purification. The purification processes for monensin and penicillin V are typical of the types of processes that are employed. In the case of monensinj, evaporation of the organic solvent from the distillation residue leaves a mixture of monensin and an oil. To this mixture is added methanol which dissolves the monensin but not the oil. The oil is removed from the solution by decantation and discarded. Addition of water to the methanol solution precipitates crystalline monensin. The product is then collected by filtration.
In the case of penicillin , the organic solvent solution from the distillation is treated with activated carbon to remove Impurities and aqueous potassium acetate solution is then added to the organic solution. The penicillin V in the organic solvent reacts with the potassium acetate to form the potassium salt of penicillin V which is insoluble in the organic solvent and precipitates. This potassium penicillin V is recovered by filtration or some other suitable means.
These two procedures are merely representative of purification processes employed in the prior art. The particular method of purification used is not a part of this invention and will vary with the particular product being purified.
The invention will be further illustrated by the following examples: Example 1 To 2 1. of penicillin V whole broth which had been assayed at 9.84 mg. of penicillin activity and 30 mg. - - of insoluble solids per ml. was added 1 1. of n-hexyl alcohol. While agitating, 20 ml. of 20 percent sulfuric acid was added to the mixture lowering the pH of the aqueous phase to 3. 9. An additional 600 ml. of hexyl alcohol was added to the mixture and the resulting slurry was distilled at a temperature of about 35°C, and a pressure of about 1 inch mercury absolute until only the solvent phase remained. Near the end of the distillation 400 ml. additional n-hexyl alcohol was added to the boil-ing slurry to replace the solvent which had been removed in the azeotrope. The dry slurry was filtered and the solids washed with 200 ml. of fresh hexyl alcohol to remove the occluded activity-laden n-hexyl alcohol. The total solvent phase contained 14 .2 g. of penicillin activity.
To illustrate the method of purifying penicillin removed from the broth in this manner, a portion of the filtrate containing 7. 90 g. of penicillin activity was treated with 10 ml. of 80 percent potassium acetate. The mixture was slurried for 30 minutes and filtered to remove precipitated penicillin V potassium salt. Recovery was 6. 13 go of penicillin activity.
Example 2 To 900 ml. of penicillin V whale broth having a pH of 3 »2 and a potency of 9.56 mg. of penicillin activity and 27 mg. insoluble solids per ml. was added 3 1. of amyl acetate. The mixture was azeotropically distilled at about 28°C. and a vacuum of about 1-inc mercury absolute until only the solvent phase remained. The dry slurry was filtered and the solids washed with 200 ml. of - - fresh am l acetate. The total solvent phase measured I050 ml. and the potency was 4.43 mg. of penicillin activity per ml. of solution. A portion of the solution was purified by crystallization as in Example 1.
Example 3 To 1 1. of monensin whole broth assayed at 2.26 mg. of activity per ml. was added I5OO ml. of n-hexyi alcohol. The mixture was azeotropically distilled at 98°C, at atmospheric pressure until only the solvent phase re-mained. The slurry was cooled, filtered, and the solids washed with 100 ml. of fresh n-hexyl alcohol. . The filtrate was evaporated under vacuum at about 30°C. until only an oil phase remained. To the oil was added 500 ml. of methanol and the mixture separated into an oil phase and a methanol phase. . The methanol contained I.89 g. of monensin activity. A portion of the monensin was recovered by concentrating the methanol solution and adding water. The crystalline monensin was recovered by filtration.
Example 4 To a continuous falling film evaporator was charged 35 -1. of benzyl alcohol. The evaporator was operated under vacuum of 27.5 inches of mercury at a temperature of 50°C. while the solvent was circulated in the system at a rate of four gallons per minute. To the evaporator were continuously changed 50 1. per hour of monensin whole broth containing 8.75 mg. of activity per ml. and 27 1. per hour of fresh benzyl alcohol. The azeo-trope was condensed overhead, and the slurry of dry solids and monensin-rich solvent was discharged periodically from the evaporator so as to maintain a constant volume of about 35 1. in the evaporator body. The solvent was de- for canted from the solids and assayed -ftrom-monensin activity. The overall recovery of monensin by this process was 90 percent from whole broth to the solvent extract.
Example 5 To a 300-gallon distillation pot containing 200 gallons of n-hexyl alcohol was slowly charged 100 gallons of fermentation broth containing the extracellular bac-terial polysaccharide, dextran, which had been produced by the microorganism Xanthomonas campestris, NRRL B-1459.
The broth contained about three percent solids by weight, and had a viscosity of 7800 cp. Viscosity is an indie. tor of the polysaccharide concentration and molecular weight.
The mixture was azeotropically distilled at 98°C. while the azeotrope was condensed overhead. At the end of the run the temperature was allowed to increase to 102 °C. in The dextran, which is insoluble /n-hexyl alcohol, was collected by filtration and dried with hot air at 160°F. The dry, oil-free polysaccharide product was stable during prolonged storage. On reconstituting the product with water to the Initial volume the viscosity measured 7,100 cp.
Example 6 This example illustrates the recovery of cephalosporin P from cephalosporin C whole broth. Cephalosporin P is a microbial steroid present in trace amounts in cephalosporin C whole broth. This steroid is difficult to purify and recover. A mixture of 150 ml. of cephalo-sporin C whole broth whose pH had been adjusted to 10.5 - - using 5 N sodium hydroxide and 250 ml. of n-hexyl alcohol was azeotroplcally distilled under vacuum at a temperature of about 35°C„ until a single liquid -phase remained. The solvent phase was decanted from the solids and assayed for cephalosporin P by paper chromatography. Within the accuracy of the assay the cephalosporin P had been entirely recovered in the solvent. Separation of the cephalosporin P from the solvent was accomplished by evaporation.
Example 7 A mixture of 200 ml. of cephalosporin C whole broth containing 6.8Ο mg. activity per ml. and 200 ml. of n-hexyl alcohol was azeotroplcally distilled under vacuum at a temperature of about 30°C. until there remained only a suspension of solids in a single liquid phase. The slurry was filtered and the solids dried at 120°F. Analysis of the solids for cephalosporin C activity showed that 78 percent of the solvent insoluble cephalosporin C had been recovered in the dry solid product.
Example 8 A mixture of 200 ml. of tylosin whole broth containing 150 mg. of activity per ml. and whose pH had been adjusted to 9.5 using 1 N sodium hydroxide and 250 ml. of n-hexyl alcohol was azeotropically distilled under vacuum at a temperature of about 30°C. until only one liquid phase remained.' The distillation residue was filtered, and the filtrate was shown by analysis to contain the tylosin activity.
Example 9 Citric acid is an organic acid produced by fer-mentation. Its solubility in water at 20°C. is 207 mg. per ml. while it is only 65 mg, per ml, in benzyl alcohol. This makes recovery by extraction difficult due to the poor distribution coefficient of citric acid between water and benzyl alcohol. However, Citric acid can be recovered from broth into benzyl alcohol following the procedure of Example 8 using citric acid whole broth rather than tylo-sin whole broth and benzyl alcohol rather than hexy alcohol.
Example .10 The exoenzyme, Arylamidase III, produced by the microorganism Cephalosporium acremonlum is soluble in water but highly insoluble in /Morgan!c solvents. A whole broth containing a specific activity of 670 units per milligram of protein can be azeotropically distilled with n-hexyl alcohol until there is only one liquid phase. The insoluble enzyme is separated from the distillation residue by filtration.
A similar separation can be conducted using benzyl alcohol rather than n-hexyl alcohol, Example 11 Twenty-five hundred milliliters of cephalosporin C whole broth was assayed at a potency of 5. 2 mg./ml.
The N-chloroacetyl cephalosporin C derivative was prepared by treating the whole broth with nine equivalents of the mixed proplonic-chloroacetic anhydride. To the broth was then added 2500 ml. of cyclohexanone and the mixture was azeotropically distilled at 0°C. and 20 mm. mercury pressure. When only one liquid phase remained, the slurry was filtered and the solids were washed with one liter of cyclohexanone to remove the N-chloroacetyl cephalosporin C adsorbed on the solids. There was obtained 1 90 ml. of solvent with antibiotic activity, representing a recovery of 82.4 percent.
Example 12 Two hundred -fifty gallons of cephalosporin C whole broth was assayed at a potency of 5.61 mg./ml. The n-chloroacetyl cephalosporin C derivative was prepared by treating testing- the whole broth with seven equivalents of the mixed propionic -chloroacetic anhydride. Two hundred - fifty gallons of eyelohexanone was then added and the mixture was azeotropically distilled in a recirculation evaporator at 50°C. and 60 mm. mercury pressure. When only one liquid phase remained the slurry was filtered . Seventy-five gallons of solvent with antibiotic activity was obtained, a recovery of 5 percent.
Claims (10)
1. A method for separating a / fermentation product which does not boil below about 200°C . from the aqueous fermentat ion broth characterized by add ing to the broth an organic solvent which f orms an azeotrope with water and in which water is soluble to an extent of less than about 10 g o per 100 g „ of solvent at 5° C , s ubject ing t he mixture to azeotrdplc distillation to remove water unt il t he water remaining is soluble in the organic sol vent , and recovering the fermentation product from the d istillation residue, the amount of organic solvent added to the fermentation broth being in excess of the amount needed t o azeotropically remove the water .
2. „ The method of claim 1 characterized in that the fermentation prod uct is in solution in t he broth.
3. . The method as in claim 2 characterized in that the fermentation product is soluble in the organic solvent .
4. The method as in claim 3 wherein the fermentation product is penicillin V, penicillin G, tylos in or erythromycin.
5. The method of claim 3 characterized in that the fermentation product is N-chloroacetyl cephalosporin C .
6. The method of claim 2 character ized in that the fermentation product is insoluble in the organic solvent .
7. The method of claim 6 characterized in that the fermentation product is cephalosporin C .
8. The method of claim 1 characterized, in that the fermentation product is insoluble In the aqueous fer - mentation broth .
9. The method of claim 8 characterized in that the fermentation product is soluble in the organic solvent .
10. The method as in claim 9 characterized in that the fermentation product is monensin. AGENTS FOR APPLICANTS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87351069A | 1969-11-03 | 1969-11-03 | |
| US7573670A | 1970-09-25 | 1970-09-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL35521A0 IL35521A0 (en) | 1970-12-24 |
| IL35521A true IL35521A (en) | 1973-10-25 |
Family
ID=26757226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL35521A IL35521A (en) | 1969-11-03 | 1970-10-25 | Method for separating fermentation products |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE758351A (en) |
| CA (1) | CA944714A (en) |
| DE (1) | DE2054085A1 (en) |
| DK (1) | DK129058B (en) |
| FR (1) | FR2068968A5 (en) |
| GB (1) | GB1296584A (en) |
| IE (1) | IE34692B1 (en) |
| IL (1) | IL35521A (en) |
| NL (1) | NL7016106A (en) |
| SE (1) | SE373037B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005095629A1 (en) * | 2004-03-29 | 2005-10-13 | Dsm Ip Assets B.V. | Process for the preparation of enantiomerically enriched esters and alcohols by means of azeotropically dried enzyme compositions |
-
0
- BE BE758351D patent/BE758351A/en unknown
-
1970
- 1970-10-25 IL IL35521A patent/IL35521A/en unknown
- 1970-10-30 DK DK552570AA patent/DK129058B/en unknown
- 1970-11-02 SE SE7014711A patent/SE373037B/xx unknown
- 1970-11-02 CA CA097,122A patent/CA944714A/en not_active Expired
- 1970-11-02 GB GB1296584D patent/GB1296584A/en not_active Expired
- 1970-11-03 FR FR7039596A patent/FR2068968A5/fr not_active Expired
- 1970-11-03 IE IE1400/70A patent/IE34692B1/en unknown
- 1970-11-03 NL NL7016106A patent/NL7016106A/xx unknown
- 1970-11-03 DE DE19702054085 patent/DE2054085A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BE758351A (en) | 1971-05-03 |
| IE34692B1 (en) | 1975-07-23 |
| PL72822B1 (en) | 1974-08-30 |
| DE2054085A1 (en) | 1971-05-19 |
| SE373037B (en) | 1975-01-27 |
| GB1296584A (en) | 1972-11-15 |
| FR2068968A5 (en) | 1971-09-03 |
| IL35521A0 (en) | 1970-12-24 |
| IE34692L (en) | 1971-05-03 |
| DK129058B (en) | 1974-08-12 |
| CA944714A (en) | 1974-04-02 |
| NL7016106A (en) | 1971-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6207428B1 (en) | Process for the isolation of clavulanic acid and of pharmaceutically acceptable salts thereof from the fermentation broth of streptomyces sp. P 6621 FERM P 2804 | |
| US20090162905A1 (en) | Method for Purification of Hyaluronic Acid Salt | |
| US4072569A (en) | Preparation of clavulanic using Streptomyces jumonjinensis | |
| US6110699A (en) | Process for producing 6-amino-penicillanic acid and phenylacetic acid | |
| IL35521A (en) | Method for separating fermentation products | |
| CA2226683C (en) | Isolation of clavulanic acid from fermentation broth by ultrafiltration | |
| EP0941229B1 (en) | Purification of fermented clavulanic acid | |
| US4696817A (en) | Extraction of teichomycin A2 from whole culture fermentation broth | |
| EP0522517B1 (en) | Process for recovering a solid component from a solid composition by clarification and extraction | |
| US4010167A (en) | Method for the recovery of zearalenone | |
| US4719287A (en) | Higher alkyl pyrrolidone extractants for water soluble phenolic or carboxylic antibiotics | |
| JP2594322B2 (en) | Purification method of hyaluronic acid | |
| AT298374B (en) | Process for the separation of a fermentation product which does not boil below 200 ° C | |
| PL72822B2 (en) | ||
| Bienkowski et al. | Evaluation of separation and purification processes in the antibiotic industry | |
| US20010029038A1 (en) | Purification of fermented clavulanic acid | |
| US4137405A (en) | Isolation of antibiotic Cephamycin C | |
| JPS6326118B2 (en) | ||
| SE203061C1 (en) |